Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Liu, Z; Le, K; Zhou, X; Alexander, JL; Lin, S; Bewshea, C; Chanchlani, N; Nice, R; McDonald, TJ; Lamb, CA; Sebastian, S; Kok, K; Lees, CW; Hart, AL; Pollok, RC; Boyton, RJ; Altmann, DM; Pollock, KM; Goodhand, JR; Kennedy, NA; Ahmad, T; Powell, N

Journal article

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Abstract:: Background
Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutralising antibodies against highly transmissible omicron (B.1.1.529) BA.1, and BA.4 and BA.5 (hereafter BA.4/5) SARS-CoV-2 variants, which possess the ability to evade host immunity and, together with emerging sublineages, are n... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., Chanchlani, N., Nice, R., McDonald, T. J., Lamb, C. A., Sebastian, S., Kok, K., Lees, C. W., Hart, A. L., Pollok, R. C., Boyton, R. J., Altmann, D. M., Pollock, K. M., Goodhand, J. R., … Powell, N. (2022). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Lancet Gastroenterology and Hepatology, 8(2), 145–156.

MLA Style

Liu, Z., et al. “Neutralising Antibody Potency against SARS-CoV-2 Wild-Type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab after Three Doses of COVID-19 Vaccine (CLARITY IBD): an Analysis of a Prospective Multicentre Cohort Study.” Lancet Gastroenterology and Hepatology, vol. 8, no. 2, Elsevier, 2022, pp. 145–56.

Chicago Style

Liu, Z, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, et al. 2022. “Neutralising Antibody Potency against SARS-CoV-2 Wild-Type and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease Treated with Infliximab and Vedolizumab after Three Doses of COVID-19 Vaccine (CLARITY IBD): an Analysis of a Prospective Multicentre Cohort Study.” Lancet Gastroenterology and Hepatology 8 (2): 145–56.
Share
Print